6.26
+2.12%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About XtalPi Holdings
Its shares trade on HKEX under the ticker 2228.HK. It has been listed since 13 June 2024. In the fiscal year to 31 December 2025, it reported revenue of CN¥910.5m and net income of CN¥140.4m. At that date it held total assets of CN¥11.90bn and shareholders' equity of CN¥10.93bn.
QuantumPharm Inc is a CN-based company operating in industry. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2024-06-13. QuantumPharm Inc is a China-based company principally engaged in the provision of drug discovery solutions and intelligent automation solutions. The firm operates its businesses through two segments. The Drug Discovery Solutions segment spans the full spectrum of the drug discovery and research process, providing modular standalone solutions to or collaborating with a diverse range of biotechnology and pharmaceutical companies and academic institutions for novel drug discovery endeavors. The Intelligent Automation Solutions segment includes solid-state research and development services and automated chemical synthesis services. Solid-state research and development services include computing services, wet laboratory services and comprehensive solutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 13 Jun 2024
- Employees
- 783
- Website
- xtalpi.com ↗
Leadership
Pay as last reported
- Mr. Kwok Yuen ChanChief Financial Officer, Company Secretary
- Ms. Jian Hui YangExecutive Director, since 2018
- Mr. Chao ChenGeneral Manager - Sales Departments of Decoration Materials, Shoe Materials and Household Materials of the Supply Chain System and the Department of International Business Expansion of the Group, since 2014
- Mr. Hui ChenDeputy Chief Executive Office and Financial Controller of Fujian District of the Group, since 2014
- Mr. Jinlong ChenComprehensive Service Platform Officer and Legal Risk Control Officer of the Group., since 2014
- Mr. Min Tsung ChenDeputy Chief Executive Officer of the Group, Director - Administrative System of the Group, since 2014
- Mr. Ping Yu ChimAssistant - Deputy Chief Executive Officer of the Group, General Manager - Sales and Production Departments for Chemical Fibers and Chemicals Department of the supply chain system of the Group., since 2014
- Mr. Liquan JiChief Operating Officer, since 2014
- Mr. Honghai WangDeputy Chief Executive Officer of the Group, Director - Supply Chain System of the Group, since 2014
- Ms. Yanyan WangGeneral Manager of COSTIN (Beijing) Technology Consulting Co., Ltd, since 2013
- Mr. Kai Lam WongAssistant to Chief Executive Officer and Internal Control Officer of the Group, since 2014
- Mr. Rui WuGeneral Coordinator - Technical Solutions Office of the Group, since 2014
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Drug Discovery Solutions segment serves diverse biotech and pharma clients in China.
- Intelligent Automation Solutions segment offers solid-state R&D and automated synthesis services.
- Shenzhen headquarters supports access to China's tech and biotech innovation ecosystem.
Weaknesses
- IPO listing date of 13 June 2024 indicates recent market entry.
- Limited employee count of 783 suggests potential scalability challenges.
- Operating in a single country (China) may restrict global market reach.
Opportunities
- Growing demand for drug discovery solutions in China's expanding biotech sector.
- Expansion into international markets for Intelligent Automation Solutions segment.
- Collaboration with academic institutions for advanced drug discovery projects.
Threats
- Intense competition in China's drug discovery market from established firms.
- Regulatory changes in China's biotech industry could impact operations.
- Economic downturns affecting pharmaceutical industry investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.